DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
88	慢性血栓塞栓性肺高血圧症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04600492 (ClinicalTrials.gov)	October 16, 2020	19/10/2020	THERAPY-HYBRID-BPA Trial	The Effect of Riociguat for Peak Cardiac Index on Cardiopulmonary Exercise Test in CTEPH Patients After Normalization of Pulmonary Artery Pressure by Combination Treatment of Riociguat and Balloon Pulmonary Angioplasty	Hypertension, Pulmonary	Drug: Riociguat Oral Tablet	National Hospital Organization Okayama Medical Center	Bayer Yakuhin, Ltd.	Recruiting	18 Years	85 Years	All	72	Phase 2	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04600492
(ClinicalTrials.gov)

October 16, 2020

19/10/2020

THERAPY-HYBRID-BPA Trial

The Effect of Riociguat for Peak Cardiac Index on Cardiopulmonary Exercise Test in CTEPH Patients After Normalization of Pulmonary Artery Pressure by Combination Treatment of Riociguat and Balloon Pulmonary Angioplasty

Hypertension, Pulmonary

Drug: Riociguat Oral Tablet

National Hospital Organization Okayama Medical Center

Bayer Yakuhin, Ltd.

Recruiting

18 Years

85 Years

All

Phase 2

Japan